Thelansis

 Chronic immune thrombocytopenia (ITP) is an autoimmune disease characterized by persistent low platelet counts, which leads to a high risk of uncontrolled bleeding. More severe symptoms include serious bleeding-related episodes (BREs), such as gastrointestinal bleeding, intracranial hemorrhage (ICH) and intra- or post-operative hemorrhage, which are associated with morbidity, mortality and diminished HRQoL. High mortality of Chronic immune thrombocytopenia (ITP) patients reason include severe BREs, infection, cardiovascular disease and hematologic cancer. The risk of ICH in ITP patients has been estimated at 1.5% for adults and 0.5% for children, and the risk of severe (non-ICH) bleeding is estimated at 3–20% in children and approximately 10% in adults. The risk of fatal hemorrhage has been estimated at 0.4% per year in patients 60 years. ·        In the United States, the incidence of ITP in adults varies between 16 and 39 cases per million adults ...

 Chronic immune thrombocytopenia (ITP) is an autoimmune disease characterized by persistent low platelet counts, which leads to a high risk of uncontrolled bleeding. More severe symptoms include serious bleeding-related episodes (BREs), such as gastrointestinal bleeding, intracranial hemorrhage (ICH) and intra- or post-operative hemorrhage, which are associated with morbidity, mortality and diminished HRQoL. High mortality of Chronic immune thrombocytopenia (ITP) patients reason include severe BREs, infection, cardiovascular disease and hematologic cancer. The risk of ICH in ITP patients has been estimated at 1.5% for adults and 0.5% for children, and the risk of severe (non-ICH) bleeding is estimated at 3–20% in children and approximately 10% in adults. The risk of fatal hemorrhage has been estimated at 0.4% per year in patients 60 years. ·        In the United States, the incidence of ITP in adults varies between 16 and 39 cases per million adults ...